BBIO · BridgeBio Pharma, Inc. · Executive Compensation
$67.00
+1.20 (+1.82%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$12.90B
Shares
195.49M
Volume · Oct 1
3.55M
Avg daily vol (3M)
2.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $14,944,585 |
| Thomas Trimarchi | President and Chief Financial Officer | $5,832,369 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $684,661 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $15,581,923 |
| Thomas Trimarchi | President and Chief Financial Officer | $6,502,058 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $5,663,687 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $12,158,626 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $6,651,996 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $6,674,437 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $2,957,392 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $25,626,959 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $8,677,297 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $10,054,909 |
| Michael Henderson | Chief Business Officer | $7,991,241 |
| Brian Stolz | Chief Operating Officer | $5,240,851 |
| Cameron Turtle | Ph.D.\ Chief Strategy Officer | $4,561,482 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $4,163,933 |
| Charles Homcy | Chairman of Pharmaceuticals | $1,855,805 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $26,334,063 |
| Brian Stolz | Chief Operating Officer | $8,146,313 |
| Charles Homcy | Chairman of Pharmaceuticals | $5,975,842 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $4,198,967 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $2,347,115 |
| Neil Kumar | Chief Executive Officer | $450,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hannah A. Valantine, M.D. | Class I director | Appointed | 2026-06-26 |
| Frank P. McCormick, Ph.D. | Class I director | Appointed | 2026-06-26 |
| James C. Momtazee | Class I director | Appointed | 2026-06-26 |
| Randal W. Scott | member of the Board of Directors | Resigned | 2026-06-26 |
| Thomas Trimarchi | President and Chief Financial Officer (CFO) | Appointed | 2025-03-17 |
| Brian C. Stephenson | Chief Financial Officer | Terminated | 2025-03-17 |
| Thomas Trimarchi | President and Chief Operating Officer | Appointed | 2024-07-23 |
| Frank McCormick | director | Appointed | 2023-02-23 |
| Brenton L. Saunders | member of the Board of Directors | Resigned | 2023-02-23 |
| Richard H. Scheller | member of the Board of Directors | Resigned | 2023-02-23 |
Key facts
CIK
1743881
CUSIP
10806X102
13F (30d)
13 filings
12 filers
Visit website
Investor relations